NO20055888L - Kombinasjonsterapi - Google Patents
KombinasjonsterapiInfo
- Publication number
- NO20055888L NO20055888L NO20055888A NO20055888A NO20055888L NO 20055888 L NO20055888 L NO 20055888L NO 20055888 A NO20055888 A NO 20055888A NO 20055888 A NO20055888 A NO 20055888A NO 20055888 L NO20055888 L NO 20055888L
- Authority
- NO
- Norway
- Prior art keywords
- cpt
- combination
- administration
- vascular
- warm
- Prior art date
Links
- 238000002648 combination therapy Methods 0.000 title 1
- 206010028980 Neoplasm Diseases 0.000 abstract 2
- 230000005865 ionizing radiation Effects 0.000 abstract 2
- UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 abstract 2
- 206010009944 Colon cancer Diseases 0.000 abstract 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 abstract 1
- 101150073133 Cpt1a gene Proteins 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0314097A GB0314097D0 (en) | 2003-06-18 | 2003-06-18 | Combination therapy |
| GB0316181A GB0316181D0 (en) | 2003-07-10 | 2003-07-10 | Combination therapy |
| PCT/GB2004/002624 WO2004112801A2 (en) | 2003-06-18 | 2004-06-18 | Compositions comprising zd6126 together with 5-fu, cpt-11 or 5-fu and cpt-11 having vascular damaging activity for treating e.g. colorectal cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NO20055888L true NO20055888L (no) | 2006-03-16 |
Family
ID=33542667
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20055888A NO20055888L (no) | 2003-06-18 | 2005-12-12 | Kombinasjonsterapi |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20060142239A1 (de) |
| EP (1) | EP1658084A2 (de) |
| JP (1) | JP2006527753A (de) |
| KR (1) | KR20060036058A (de) |
| AU (1) | AU2004248968A1 (de) |
| BR (1) | BRPI0411567A (de) |
| CA (1) | CA2529409A1 (de) |
| IL (1) | IL172560A0 (de) |
| MX (1) | MXPA05013827A (de) |
| NO (1) | NO20055888L (de) |
| WO (1) | WO2004112801A2 (de) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1761281A1 (de) * | 2004-06-04 | 2007-03-14 | Pfizer Products Incorporated | Verfahren zur behandlung von abnormalem zellwachstum |
| US20090118340A1 (en) * | 2007-10-12 | 2009-05-07 | Jerzy Gebicki | Method for inhibiting and/or preventing formation of cancer metastases and seconddary malignant cancers |
| JP2025532720A (ja) * | 2022-09-22 | 2025-10-02 | サムスン メディカル ファウンデーション | 腫瘍血管破壊用医薬組成物 |
| KR20250099958A (ko) * | 2023-12-26 | 2025-07-03 | 주식회사 엔도큐라 | 종양 혈관 파괴용 약학 조성물 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4864021A (en) * | 1984-10-30 | 1989-09-05 | Otsuka Pharmaceutical Co., Ltd. | 5-fluorouracil derivatives |
| GB9714249D0 (en) * | 1997-07-08 | 1997-09-10 | Angiogene Pharm Ltd | Vascular damaging agents |
| PL357282A1 (en) * | 2000-03-31 | 2004-07-26 | Angiogene Pharmaceuticals Ltd. | Divided dose therapies with vascular damaging activity |
| EE200200565A (et) * | 2000-03-31 | 2004-06-15 | Angiogene Pharmaceuticals Ltd. | Vaskulaarse kahjustava toimega kombinatsioonravi |
| GB0008269D0 (en) * | 2000-04-05 | 2000-05-24 | Astrazeneca Ab | Combination chemotherapy |
| US6720323B2 (en) * | 2000-07-07 | 2004-04-13 | Angiogene Pharmaceuticals Limited | Colchinol derivatives as angiogenesis inhibitors |
| MXPA02012905A (es) * | 2000-07-07 | 2004-07-30 | Angiogene Pharm Ltd | Derivados de colquinol como agentes de dano vascular.. |
| BR0309226A (pt) * | 2002-04-16 | 2005-02-09 | Astrazeneca Ab | Métodos para a produção de um efeito de danificação vascular em um animal de sangue quente, e para o tratamento de um câncer envolvendo um tumor sólido em um animal de sangue quente, composição farmacêutica, kit, e, usos de zd6126 ou de um seu sal farmaceuticamente aceitável, e de zd1839 ou de um seu sal farmaceuticamente aceitável |
-
2004
- 2004-06-18 JP JP2006516444A patent/JP2006527753A/ja active Pending
- 2004-06-18 MX MXPA05013827A patent/MXPA05013827A/es not_active Application Discontinuation
- 2004-06-18 WO PCT/GB2004/002624 patent/WO2004112801A2/en not_active Ceased
- 2004-06-18 KR KR1020057024244A patent/KR20060036058A/ko not_active Withdrawn
- 2004-06-18 US US10/561,183 patent/US20060142239A1/en not_active Abandoned
- 2004-06-18 CA CA002529409A patent/CA2529409A1/en not_active Abandoned
- 2004-06-18 AU AU2004248968A patent/AU2004248968A1/en not_active Abandoned
- 2004-06-18 BR BRPI0411567-8A patent/BRPI0411567A/pt not_active Application Discontinuation
- 2004-06-18 EP EP04742979A patent/EP1658084A2/de not_active Withdrawn
-
2005
- 2005-12-12 NO NO20055888A patent/NO20055888L/no not_active Application Discontinuation
- 2005-12-13 IL IL172560A patent/IL172560A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP2006527753A (ja) | 2006-12-07 |
| IL172560A0 (en) | 2006-04-10 |
| WO2004112801A3 (en) | 2005-03-24 |
| US20060142239A1 (en) | 2006-06-29 |
| WO2004112801A2 (en) | 2004-12-29 |
| KR20060036058A (ko) | 2006-04-27 |
| EP1658084A2 (de) | 2006-05-24 |
| CA2529409A1 (en) | 2004-12-29 |
| MXPA05013827A (es) | 2006-03-13 |
| AU2004248968A1 (en) | 2004-12-29 |
| BRPI0411567A (pt) | 2006-08-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO20071426L (no) | Kreft kombinasjonsbehandling omfattende AZD2171 og Imatinib | |
| NO20060307L (no) | Anvendelse av kinoazolinderivatet ZD6474 kombinert med platinaforbindelser og eventuelt ioniserende straling i behandling av sykdommer assosoiert med angiogenese og/eller okt vaskulaert permeabilitet | |
| CY1116463T1 (el) | Θεραπεια συνδυασμου για τη θεραπευτικη αγωγη διαταραχων ανεπαρκειας πρωτεϊνης | |
| DK1551409T3 (da) | Anvendelse af quinazolinderivatet ZD6474 kombineret med gemcitabin og eventuelt ioniserende stråling ved behandling af cancer | |
| NO20050807L (no) | Farmasoytiske sammensetninger som innbefatter dekstrometorfan og kinidin for behandling av neurologiske forstyrrelser | |
| ATE411022T1 (de) | Pyridylpyrrol-derivate als wirksame kinase-hemmer | |
| CZ309247B6 (cs) | 40-O-(2-hydroxyethyl)rapamycin pro použití jako jediná účinná látka při léčení solidního nádoru | |
| TR200003879T2 (tr) | İn vivo ışın tedavisine duyarlılaştırıcı özelliklere sahip farnesil protein transferaz inhibitörleri@ | |
| NO20071428L (no) | Kombinasjon inneholdende ZD6474 og Imatinib | |
| PT1017675E (pt) | Derivados da camtotecina altamente lipofilos | |
| IS6558A (is) | Blandaðar sjúkdómsmeðferðir með æðaskaðandi virkni | |
| CY1111565T1 (el) | Θεραπεια συνδυασμου του zd6474 με 5-fu και/ή cpt-11 | |
| NO20024076L (no) | Sammensetning omfattende camptotecin og et pyrimidinderivat for behandling av cancer | |
| NO20050528L (no) | Kombinasjon av VEGF reseptor tyrosin kinase inhibitorer for behandling av kreft | |
| BR0316458A (pt) | Composto, composição farmacêutica, método de tratamento ou prevenção de doenças, método para intensificar a cognição em um paciente saudável, e, uso de um composto | |
| DE60313754D1 (de) | Botanischer extrakt mit antikrebs-aktivität enthaltend isoliquiritigenin | |
| NO20044498L (no) | Kombinasjonsterapi for behandling av cancer | |
| ATE290388T1 (de) | Kombination von selen-haltigen verbindungen mit gemcitabin oder mitomycin c | |
| BR0309996A (pt) | Composto, composição farmacêutica, método de tratar ou melhorar doenças ou condições proliferativas, uso de um composto, e, método de tratar ou melhorar doenças inflamatórias | |
| NO20076657L (no) | Kombinasjonsterapi av cancer med AZD2171 og gemcitabin | |
| NO20055888L (no) | Kombinasjonsterapi | |
| NO20056170L (no) | Kreftkombinasjonsterapi omfattende AZD2171 of ZD1839 | |
| NO20064753L (no) | Kombinasjonsterapi | |
| DE60334289D1 (de) | Dithiolopyrrolon-derivate zur behandlung von proliferativen störungen | |
| TW200500073A (en) | Pharmaceutical composition comprising an indolopyrrolocarbazole derivative and use thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC2A | Withdrawal, rejection or dismissal of laid open patent application |